Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 50%Moderate 1 · 25%High 0 · 0%

Idraparinux vs usual care

All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis

Idraparinux showed no clear difference in all‐cause mortality compared with standard therapy (low certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 1.14 [0.69, 1.86]
1 study · 2904 participants
Low

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

All‐cause mortality · people with cancer with VTE receiving secondary prophylaxis

Idraparinux secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (moderate certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 1.11 [0.78, 1.59]
1 study · 284 participants
Moderate

Low molecular weight heparin and idraparinux vs usual care

All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Idrabiotaparinux vs idraparinux

All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis

Idrabiotaparinux showed no clear difference in all‐cause mortality compared with idraparinux (low certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 0.48 [0.18, 1.27]
1 study · 757 participants
Low